Overview

• The University of Leicester team reported roughly 15% fewer cancers among people who had bariatric surgery and about 12% fewer among those prescribed semaglutide.
• The observational study drew on real-world data for around 180,000 adults with overweight or obesity and type 2 diabetes.
• Researchers compared cancer incidence across groups receiving semaglutide, tirzepatide, bariatric surgery, or standard diabetes medications.
• The analysis focused on obesity-associated cancers including breast, colorectal, gallbladder, liver, ovarian, pancreatic and uterine cancers.
• Authors emphasized the findings show associations rather than causation and called for randomized trials to confirm effects and clarify outcomes for newer drugs.